{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:25:28Z","timestamp":1789655128111,"version":"4.0.1"},"reference-count":26,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T00:00:00Z","timestamp":1611619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Acinetobacter baumannii has emerged as a significant concern worldwide. The mortality rate of carbapenem-resistant A. baumannii (CRAB) is increasing, especially in the intensive care unit (ICU). Thus, the objective of this study is to compare the efficacy and safety of colistin plus vancomycin for the treatment of critically ill patients with CRAB in Chiang Mai University Hospital. We conducted a retrospective cohort study of critically ill patients in the ICU with CRAB infection who received colistin alone or colistin-vancomycin combination therapy at Chiang Mai University Hospital. A total of 365 critically ill patients met the inclusion criteria. The results in this study showed that after propensity score matching, colistin plus vancomycin showed no significant differences in the 30-day mortality compared to colistin alone. Likewise, for colistin plus vancomycin, compared with colistin therapy alone, there were no significant differences in the clinical response, microbiological response and nephrotoxicity. In conclusion, colistin plus vancomycin was no significant differences in 30-day mortality, clinical response, microbiological response compared to colistin alone for infections due to CRAB. The nephrotoxicity rates were similar for both groups, so colistin combination with vancomycin was not necessary for the management of infection caused by CRAB.<\/jats:p>","DOI":"10.3390\/pharmaceutics13020162","type":"journal-article","created":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T08:29:16Z","timestamp":1611649756000},"page":"162","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Clinical Efficacy and Nephrotoxicity of Colistin Alone versus Colistin Plus Vancomycin in Critically Ill Patients Infected with Carbapenem-Resistant Acinetobacter baumannii: A Propensity Score-Matched Analysis"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7665-8819","authenticated-orcid":false,"given":"Wasan","family":"Katip","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand"},{"name":"Epidemiology Research Group of Infectious Disease (ERGID), Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peninnah","family":"Oberdorfer","sequence":"additional","affiliation":[{"name":"Epidemiology Research Group of Infectious Disease (ERGID), Chiang Mai University, Chiang Mai 50200, Thailand"},{"name":"Division of Infectious Diseases, Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,1,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1093\/ofid\/ofu052.203","article-title":"337: Nosocomial Transmission of Carbapenem-Resistant Acinetobacter baumannii (CRAb) among ICU Patients Detected by CRAb-LAMP","volume":"1","author":"Yamamoto","year":"2014","journal-title":"Open Forum Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/1469-0691.12716","article-title":"A case-control study to identify predictors of 14-day mortality following carbapenem-resistant Acinetobacter baumannii bacteraemia","volume":"20","author":"Nutman","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ayoub Moubareck, C., and Hammoudi Halat, D. (2020). Insights into Acinetobacter baumannii: A Review of Microbiological, Virulence, and Resistance Traits in a Threatening Nosocomial Pathogen. Antibiotics, 9.","DOI":"10.3390\/antibiotics9030119"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s13756-020-00824-4","article-title":"Influence of severity of infection on the effect of appropriate antimicrobial therapy for Acinetobacter baumannii bacteremic pneumonia","volume":"9","author":"Kang","year":"2020","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_5","first-page":"200","article-title":"Colistin in critically ill patients","volume":"79","author":"Boisson","year":"2013","journal-title":"Minerva Anestesiol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1097\/CCM.0B013E3181652FAE","article-title":"Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: A matched case-control study","volume":"36","author":"Matthaiou","year":"2008","journal-title":"Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1128\/AAC.00103-06","article-title":"Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii","volume":"50","author":"Li","year":"2006","journal-title":"Antimicrob. Agents Chemother"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ijantimicag.2016.09.014","article-title":"Synergistic combinations of polymyxins","volume":"48","author":"Lenhard","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1590\/0037-8682-0081-2014","article-title":"Colistin and anti-Gram-positive bacterial agents against Acinetobacter baumannii","volume":"47","author":"Liu","year":"2014","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Aitullina, A., Purvi\u0146a, S., and Kr\u016bmi\u0146a, A. (2020). Colistin co-administration with other nephrotoxins: Experience of teaching hospital of Latvia. Int. J. Clin. Pharm.","DOI":"10.1007\/s11096-020-01154-6"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ajic.2008.03.002","article-title":"CDC\/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting","volume":"36","author":"Horan","year":"2008","journal-title":"Am. J. Infect. Control"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"c182","DOI":"10.1159\/000142926","article-title":"Definition and classification of acute kidney injury","volume":"109","author":"Kellum","year":"2008","journal-title":"Nephron Clin. Pract."},{"key":"ref_14","unstructured":"CLSI (2015). Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement, Clinical and Laboratory Standards Institute. CLSI document M100-S25."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jiac.2018.09.011","article-title":"Changes in the early mortality of adult patients with carbapenem-resistant Acinetobacter baumannii bacteremia during 11 years at an academic medical center","volume":"25","author":"Choi","year":"2019","journal-title":"J. Infect. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1089\/mdr.2019.0088","article-title":"Synergistic Activities of Colistin Combinations with Meropenem, Sulbactam, Minocycline, Disodium Fosfomycin, or Vancomycin Against Different Clones of Carbapenem-Resistant Acinetobacter baumannii Strains","volume":"26","author":"Sertcelik","year":"2020","journal-title":"Microb. Drug Resist."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5316","DOI":"10.1128\/AAC.00922-10","article-title":"Potent synergy and sustained bactericidal activity of a vancomycin-colistin combination versus multidrug-resistant strains of Acinetobacter baumannii","volume":"54","author":"Gordon","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s40121-014-0051-9","article-title":"A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii","volume":"3","author":"Claeys","year":"2014","journal-title":"Infect. Dis. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Ceccarelli, G., Oliva, A., d\u2019Ettorre, G., D\u2019Abramo, A., Caresta, E., Barbara, C.S., Mascellino, M.T., Papoff, P., Moretti, C., and Vullo, V. (2015). The role of vancomycin in addition with colistin and meropenem against colistin-sensitive multidrug resistant Acinetobacter baumannii causing severe infections in a Paediatric Intensive Care Unit. BMC Infect. Dis., 15.","DOI":"10.1186\/s12879-015-1133-3"},{"key":"ref_20","first-page":"205","article-title":"Clinical and in vitro efficacy of colistin plus vancomycin and rifampin against colistin-resistant Acinetobacter baumannii causing ventilator-associated pneumonia","volume":"40","author":"Oliva","year":"2017","journal-title":"New Microbiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e01925-19","DOI":"10.1128\/AAC.01925-19","article-title":"Antagonistic Effect of Colistin on Vancomycin Activity against Methicillin-Resistant Staphylococcus aureus in In Vitro and In Vivo Studies","volume":"64","author":"Choi","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1159\/000356004","article-title":"Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"59","year":"2013","journal-title":"Chemotherapy"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1128\/AAC.00871-13","article-title":"Clinical experience of colistin glycopeptide combination in critically ill patients infected with Gram-negative bacteria","volume":"58","author":"Petrosillo","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1128\/AAC.01585-08","article-title":"Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): Implications for dosing in MRSA pneumonia","volume":"53","author":"Harigaya","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.10-0463","article-title":"Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration","volume":"138","author":"Imberti","year":"2001","journal-title":"Chest"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"7240","DOI":"10.1128\/AAC.00554-15","article-title":"Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients","volume":"59","author":"Karaiskos","year":"2015","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/2\/162\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:15:33Z","timestamp":1760159733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/13\/2\/162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,26]]},"references-count":26,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2]]}},"alternative-id":["pharmaceutics13020162"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics13020162","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,26]]}}}